EX-23.2 5 a2025forms-8exhibit232.htm EX-23.2 Document

Exhibit 23.2


Consent of Independent Registered Public Accounting Firm

We consent to the use of our report dated March 8, 2023, except for note 18, as to which the date is March 6, 2025, with respect to the consolidated financial statements of Xeris Biopharma Holdings, Inc., incorporated herein by reference.
/s/ KPMG LLP
Chicago, Illinois
March 6, 2025